| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Animal experiment: | The mice are untreated or given an i.p. injection of the vehicle (1% DMSO) or 0.2-mg/kg BW245C. Thirty minutes after the injection, the mice are anesthetized and placed on a thermoregulated pad to maintain body temperature, and 3 mm of the tail tip is excised. The tail is immediately dipped in warm PBS (37.0±0.5℃) and time to visible cessation of bleeding is recorded. |
| 产品描述 | Target: DP1 receptor IC50: 2.5 nM Ki: 0.9 nM BW 245C is a kind of prostaglandin analogue with stable chemical properties which functions as a potent inhibitor of platelet aggregation. BW 245C could selectively active the DP1 receptor, and inhibit [3H]-PGD2 binding to isolated human platelet membranes, with the Ki value of 0.9 nM [1]. In Vitro: BW 245C could inhibit the aggregation of human and rat platelets induced by ADP in a dose dependent manner, with the IC50 values of 8.7 nM and 9.9 nM, respectively [1]. Besides, in HEK293 cells stably expressing the hDP receptor, BW 245C could significantly increase cAMP production, with the EC50 value of 0.7 nM [2]. In Vivo: In spontaneously hypertensive rats, intravenous bolus injection with BW 245C at the dose of 250 μg/kg could reduce the systolic and diastolic blood pressure by 23% and 34%, respectively [1]. Clinical trial: In four healthy male volunteers, intravenous injection of BW 245C (1, 2 and 4 ng kg-1 min-1) exerted a progressive increase in heart rate and pulse pressure [3]. References: |
m.cnreagent.com